Biomarkers for neurodegenerative diseases
O Hansson - Nature medicine, 2021 - nature.com
Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
the clinic but also to facilitate the development and monitoring of effective disease-modifying …
The amyloid cascade hypothesis: an updated critical review
Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …
disease have created excitement and have been heralded as corroboration of the amyloid …
Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade
Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …
imaging of several metabolic processes, blood flow measurements, regional chemical …
[HTML][HTML] The China alzheimer report 2022
R Ren, J Qi, S Lin, X Liu, P Yin, Z Wang, R Tang… - General …, 2022 - ncbi.nlm.nih.gov
China's population has rapidly aged over the recent decades of social and economic
development as neurodegenerative disorders have proliferated, especially Alzheimer's …
development as neurodegenerative disorders have proliferated, especially Alzheimer's …
The human connectome in Alzheimer disease—relationship to biomarkers and genetics
The pathology of Alzheimer disease (AD) damages structural and functional brain networks,
resulting in cognitive impairment. The results of recent connectomics studies have now …
resulting in cognitive impairment. The results of recent connectomics studies have now …
EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3
The present procedural guidelines summarize the current views of the EANM Neuro-
Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine …
Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine …
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort …
T West, KM Kirmess, MR Meyer, MS Holubasch… - Molecular …, 2021 - Springer
Background The development of blood-based biomarker tests that are accurate and robust
for Alzheimer's disease (AD) pathology have the potential to aid clinical diagnosis and …
for Alzheimer's disease (AD) pathology have the potential to aid clinical diagnosis and …
Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum
Importance One characteristic histopathological event in Alzheimer disease (AD) is cerebral
amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and …
amyloid aggregation, which can be detected by biomarkers in cerebrospinal fluid (CSF) and …
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau
S Janelidze, S Palmqvist, A Leuzy… - Alzheimer's & …, 2022 - Wiley Online Library
Introduction We studied usefulness of combining blood amyloid beta (Aβ) 42/Aβ40,
phosphorylated tau (p‐tau) 217, and neurofilament light (NfL) to detect abnormal brain Aβ …
phosphorylated tau (p‐tau) 217, and neurofilament light (NfL) to detect abnormal brain Aβ …